Large Randomised Lipid Modification Trials

Lead Research Organisation: Medical Research Council

Abstract

Heart disease and stroke are the leading causes of death and disability in the developed and developing world. Blood fats (cholesterol) along with smoking and blood pressure are major causes of these problems. CTSU has run a series of large trials of cholesterol lowering using statins which have provided clear evidence of the benefits of such treatment. Statins lower the blood cholesterol and have been shown to substantially reduce the risk of heart attacks and stroke in a wide variety of people at high-risk of these conditions. These studies have resulted in worldwide changes in clinical practice and very widespread use of statins. However, despite the benefits of statin treatment, some people remain at risk of heart disease and stroke. Further research is required on the long term benefits and risks of therapy in different groups and newer lipid modifying drugs are needed to provide additional benefits. The effects of these newer drugs on the background of statin treatment are likely to be modest so evidence is required from very large randomised studies in order to provide reliable answers about the benefits or otherwise.

Technical Summary

Along with smoking and blood pressure, blood lipids are a major cause of cardiovascular disease, which remains the leading cause of morbidity and mortality in the developed and developing world. Higher levels of LDL cholesterol and lower levels of HDL cholesterol are associated with higher risks of coronary heart disease. This programme continues the long-running series of large scale trials of lipid modification (both LDL-lowering and HDL-raising) that have been coordinated by CTSU over the last two decades. These studies include the MRC/BHF Heart Protection Study (1993-2001) which assessed the effects of a statin versus placebo in 20,000 high risk patients, SEARCH (1998-2008) which compared more intensive versus standard dose statin, SHARP (2003-2010) which assessed statin plus ezetimibe versus placebo in 9000 patients with chronic kidney disease, HPS2-THRIVE (2006-2012) which assessed niacin and REVEAL (2011-ongoing) which is assessing anacetrapib. These studies and associated meta-analyses (including those conducted by CTSU) have resulted in widespread use of statins, which effectively lower LDL cholesterol, for the primary and secondary prevention of cardiovascular disease. However, there have been questions about their long-term safety and efficacy in different populations. Although statins are widely available and highly cost-effective, some patients remain at high risk despite statin use, thus additional safe treatments to modify risk are needed. Attention is now turning to newer drugs which modulate lipids by other mechanisms. The effects of such additional treatments on top of statins are likely to be modest, so large-scale randomised evidence is required to assess their effects reliably. The HPS2-THRIVE trial assessed the effects of niacin (a lipid-modifying drug used for 50 years) on a background of statin therapy in 25,000 high cardiovascular risk patients from the UK, Scandinavia and China. Niacin raises HDL and lowers LDL-cholesterol but the effects are small. HPS2-THRIVE showed no cardiovascular benefit with niacin and, furthermore, niacin caused substantial harms, including increased diabetes, infections and bleeding. The results led to the niacin preparation being withdrawn. The HPS3-TIMI-55-REVEAL study is currently testing the value of a new inhibitor of the cholesteryl ester transfer protein which raises HDL cholesterol and lowers LDL cholesterol substantially. Over 30,000 patients from Europe, North America and China who are at high cardiovascular risk and already on effective statin treatment have been randomised to receive anacetrapib or placebo and are currently being followed up. Studies of other promising lipid-modifying drugs are also being considered.

Organisations

Publications

10 25 50
publication icon
3C Study Collaborative Group (2018) Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial. in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

publication icon
Alfirevic A (2014) Phenotype standardization for statin-induced myotoxicity. in Clinical pharmacology and therapeutics

publication icon
Armitage J (2014) Misrepresentation of statin safety evidence in The Lancet

publication icon
Armitage, J. (2009) Epidemiological aspects of lipid and lipoprotein levels in relation to cardiovascular diseases in Evidence-based Management of Lipid Disorders. (eds: Vissers M, Kastelein J, Stroes E)

publication icon
ASCEND Study Collaborative Group (2018) Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. in The New England journal of medicine

 
Description THRIVE
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact As a result of the results Merck stopped development of the Combined ER niaicn/laropiprant combination drug and the EMA licence for Tredaptive (the marketed name) was withdrawn.
 
Description US Food and Drug Administration (FDA) change to drug labelling for Vytorin (simvastain and ezetimibe)
Geographic Reach North America 
Policy Influence Type Participation in a advisory committee
Impact The results of the SHARP trial resulted in the FDA's Endocrinologic and Metabolic Drugs Advisory Committee approving a change in the drug label for Vytorin to state that there was compelling evidence on the benefit of cholesterol-lowering with the drug in patients with chronic kidney disease.
URL http://www.sharpinfo.org/FDA_approval_PR_2012-01-25.pdf
 
Description ASCEND study of cognitive function
Amount £155,000 (GBP)
Funding ID ARUK-GCTF2016B-2 
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2016 
End 07/2018
 
Description BHF grant for ASCEND
Amount £1,078,553 (GBP)
Funding ID SP/14/331114 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2015 
End 12/2018
 
Description Research Excellence Award
Amount £2,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2014 
End 08/2014
 
Description Research grant
Amount £371,000 (GBP)
Organisation Merck 
Sector Private
Country Germany
Start 06/2003 
End 09/2010
 
Description Research grant (BHF chair)
Amount £2,762,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2014 
End 03/2019
 
Description Research grant (BHF chair)
Amount £3,286,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2008 
End 03/2014
 
Description Research grant (HPS2)
Amount £52,772,000 (GBP)
Organisation Merck 
Sector Private
Country Germany
Start 12/2005 
End 06/2015
 
Description Research grant (HPS3 Adipose substudy)
Amount £880,220 (GBP)
Organisation Merck 
Sector Private
Country Germany
Start 03/2014 
End 12/2020
 
Description Research grant (HPS3)
Amount £99,838,000 (GBP)
Organisation Merck 
Sector Private
Country Germany
Start 03/2010 
End 12/2020
 
Description Research grant (SEARCH)
Amount £22,727,000 (GBP)
Organisation Merck 
Sector Private
Country Germany
Start 01/2003 
End 12/2009
 
Description Research grant (SHARP)
Amount £39,689,000 (GBP)
Organisation Merck 
Sector Private
Country Germany
Start 01/2003 
End 11/2014
 
Description Research grant (STICS)
Amount £61,000 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 12/2011 
End 09/2016
 
Description ASCEND Collaboration 
Organisation Cheltenham General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution joint academic collaboration
Collaborator Contribution enhance eye outcomes from ASCEND trial
Impact n/a
Start Year 2016
 
Description BEST-D Collaboration 
Organisation New York University
Country United States 
Sector Academic/University 
PI Contribution joint academic collaboration
Collaborator Contribution provided expertise on endocrinology of bone disease collaboration
Impact provided expertise on endocrinology of bone disease collaboration
Start Year 2009
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Aalborg University Hospital
Department Aalborg University Hospital, South
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Aberdeen Royal Infirmary
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Addenbrooke's Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Affiliated Hospital of Medical College Qingdao University
Department Department of Emergency
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Affiliated Hospital of Medical College Qingdao University
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Affiliated Hospital of Xuzhou Medical College
Department Department of Endocrinology and Metabolism
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Affiliated Hospital of Xuzhou Medical College
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Aleris Health Center Bollnas
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Alingsas lasarett
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Anshan Shuangshan Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Baogang Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Baogang Hospital
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Barnsley Hospital NHS Foundation Trust
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Bedford Hospital NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Beijing Chao-Yang Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Bergslagen Hospital
Department My Heart
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Birmingham City Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Blackpool Victoria Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Blekinge Hospital
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Bradford Royal Infirmary
Country United Kingdom 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Bristol Royal Infirmary
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Central Denmark Region
Department Randers Regional Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Central Hospital
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Central Hospital in Kristianstad
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Cheltenham General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation China-Japan Union Hospital of Jilin University
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Conquest Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation County Hospital, Stafford
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Dalecarlia Clinical Research Center
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Dalecarlia Clinical Research Center
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Danderyd Hospital
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Darlington Memorial Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Derriford Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Dewsbury District Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Dorset County Hospital NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation East Lancashire Hospitals NHS Trust
Department Royal Blackburn Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Eastbourne District General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Etelä-karjalan Keskussairaala / Etela-Karjalan keskussairaala
Country Finland 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation FAW General Hospital
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Fana Hjertesenter AS
Country Norway 
Sector Charity/Non Profit 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation First Affiliated Hospital of China Medical University
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation First Affiliated Hospital of China Medical University
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation First Affiliated Hospital of Zhengzhou University
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation First Affiliated Hospital of Zhengzhou University
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation First Hospital of Jilin University
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation First Hospital of Jilin University
Department Department of Endocrinology and Metabolism
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation First People's Hospital Of Shenyang
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation First People's Hospital Of Shenyang
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Fourth Affiliated Hospital Of China Medical University
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Frenchay Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Fu Wai Hospital
Department Cardiac Surgery Center
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Fu Wai Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Gentofte Hospital
Department Cholesterol Laboratory
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Gentofte Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Gentofte Hospital 2
Department Cholesterol Laboratory 2
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Gentofte Hospital 2
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Glan Clwyd District General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Glenfield Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Glostrup Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Haderslev Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Halsobolaget i Jarfalla AB
Country Sweden 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Haukeland University Hospital
Country Norway 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Health Center Silentzvägen
Country Sweden 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Heimdal Helsehus Legesenter AS, Norway
Country Norway 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Helse Forde HF
Country Norway 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Helse Sunnmmore HF
Country Norway 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Helsingin Yliopisto, Kansanterveystieteenlaitos, Finland
Country Finland 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Helsingin Yliopisto, Kansanterveystieteenlaitos, Finland
Country Finland 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Helsingin Yliopisto, Kansanterveystieteenlaitos, Finland
Country Finland 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Herlev Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Herning Regional Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Hillingdon Hospital, Uxbridge
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Hjarthuset AB, Varberg, Sweden
Country Sweden 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Hjerteklinikken i Harstad AS, Norway
Country Norway 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Hoglandssjukhuset Eksjo, Sweden
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Holbæk Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Hospital of St Cross, Rugby
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Huddersfield Royal Infirmary
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Hvidovre Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Hässleholm Hospital
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Inland Hospital Kongsvinger
Country Norway 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Inner Mongolia Autonomous Region People's Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Jyvaskyla CorusFit Oy, Finland
Country Finland 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation King's Mill Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Kolding Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Kolding Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Kuusankoski Health Center
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Ladulaas Clinical Studies
Country Sweden 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Leighton Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Lindesberg Hospital
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Linköping University Hospital
Country Sweden 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Lister Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Ljungby Hospital
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Luton and Dunstable University Hospital NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Macclesfield District General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Manor Hospital Walsall
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Medical City
Department Sinsen Clinic
Country Norway 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Mediwest Seinajoki, Finland
Country Finland 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Musgrove Park Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Ninewells Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Nordsjællands Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Norfolk and Norwich University Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation North Cumbria University Hospitals NHS Trust
Department Cumberland Infirmary
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation North Manchester General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation North Tyneside General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Northampton General Hospital, Northampton
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Northern General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Northwick Park Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Næstved Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Oskarshamn's Hospital
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Oslo University Hospital
Country Norway 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Oslo University Hospital
Country Norway 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Oulu University Hospital
Country Finland 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Peking Union Medical College Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Peking University People's Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Peking University Third Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Peterborough City Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Pinderfields Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Poole Hospital NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Princess Royal Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Princess of Wales Hospital, Bridgend
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Qingdao Municipal Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Qingdao Municipal Hospital
Department Department of Emergency
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Queen Elizabeth Hospital Birmingham
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Queen's Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Queen's Medical Centre
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Rigshospitalet
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Roskilde Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal Berkshire Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal Bolton Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal Cornwall Hospitals NHS Trust
Department Royal Cornwall Hospital (Treliske)
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal Derby Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal Devon and Exeter Hospital
Country United Kingdom 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal Infirmary of Edinburgh
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal Sussex County Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal United Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal Victoria Hospital, Belfast
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Royal Victoria Infirmary
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Russells Hall Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Salford Royal Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Sandwell General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Scunthorpe General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Second Affiliated Hospital of Zhengzhou University
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Second Affiliated Hospital of Zhengzhou University
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Second Hospital Of Tianjin Medical University
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Shengjing Hospital of China Medical University
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Shenyang Fifth People's Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Shenyang Fourth People's Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Shenyang Sujiatun Central Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Singleton Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Skelleftea Hospital
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Slagelse Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Southampton General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Southwest Jutland Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Spesialistsenteret pa
Country Norway 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation St Helier's Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation St Mary's Hospital Portsmouth
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation St Richard's Hospital
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Stockholm Heart Center, Sweden
Country Sweden 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Stockport NHS Foundation Trust
Department Stepping Hill Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Sunderland Royal Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Suzhou Kowloon Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Svendborg Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The 306th Hospital of PLA
Department Department of Endocrinology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The Affiliated Hospital of Inner Mongolia Medical University
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The First Affiliated Hospital of Baotou Medical College
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The General Hospital Of AISCO
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The General Hospital Of Xuzhou Mining Group
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The General Hospital Of Xuzhou Mining Group
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The People's Hospital Of Liaoning Province
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The Rotherham NHS Foundation Trust
Department Rotherham Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
Department Royal Bournemouth Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The Royal Surrey County Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The Second Affiliated Hospital of Baotou Medical College
Department Department of Endocrinology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The Second Affiliated Hospital of Harbin Medical University
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The Second Affiliated Hospital of Harbin Medical University
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation The Walton Centre NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Third Peoples Hospital of Xuzhou
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tianjin Chest Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tianjin Fourth Central Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tianjin Medical University General Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tianjin Medical University General Hospital
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tianjin Third Central Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tianjin Third Central Hospital
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tianjin Union Medicine Centre
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tianjin Union Medicine Centre
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tiexi Hospital of Anshan
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tongji University Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Tongji University Hospital
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Torbay Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Trondheim Heart Center AS
Country Norway 
Sector Private 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation University Hospital Mas
Country Sweden 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation University Hospital of North Staffordshire NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation University Hospital of Wales
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation University Hospitals Coventry and Warwickshire NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation University of Eastern Finland
Department Kuopio Technopolis
Country Finland 
Sector Academic/University 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Viborg Regional Hospital
Country Denmark 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Victoria Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Watford General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Weifang People's Hospital
Department Department of Emergency
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation West Cumberland Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Whipps Cross University Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Whiston Hospital
Country United States 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Worcestershire Royal Hospital
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Worthing Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Wuhan Asia Heart Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Wuhan Central Hospital
Department Department of Endocrinology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Wuhan Puai Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Wuhan Puai Hospital
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Wycombe General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Wythenshawe Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Xuzhou Central Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Xuzhou Central Hospital
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Xuzhou No.1 People's Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Xuzhou No.1 People's Hospital
Department Department of Neurology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Yeovil District Hospital NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy 
Organisation Zhengzhou Central Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.
Collaborator Contribution Local collaborators screen, recruit and follow-up trial participants.
Impact THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.
Start Year 2006
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Aalborg University Hospital
Country Denmark 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Aarhus University Hospital
Country Denmark 
Sector Academic/University 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Aberdeen Royal Infirmary
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Acadia Clinical Research LLC
Country United States 
Sector Private 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Addenbrooke's Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Advanced Heart Care LLC
Country United States 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Advanced Neurology Specialists
Country United States 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Affiliated Hospital of Medical College Qingdao University
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Affiliated Hospital of Xuzhou Medical College
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Albany Associates in Cardiology
Country United States 
Sector Academic/University 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Albuquerque Clinical Trials
Country United States 
Sector Charity/Non Profit 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Ambulatory Heart Center Kassel
Country Germany 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Anshan Shuangshan Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Asheville Cardiology Associates
Country United States 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Associated Cardiovascular Consultants
Country United States 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Associated Research Partners LLC
Country United States 
Sector Private 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Atlanta Heart Specialists, LLC
Country Georgia 
Sector Private 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Austin Heart, PLLC
Country United States 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Austin Heart, PLLC
Country United States 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Aventura Heart Center
Country United States 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Awasty Research Network, LLC
Country United States 
Sector Charity/Non Profit 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Barnsley District General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Bay Area Cardiology Associates
Country United States 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Baylor College of Medicine
Department Center for Cardiovascular Disease Prevention
Country United States 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Bedford Hospital NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Beijing Chao-Yang Hospital
Department Department of Cardiology
Country China 
Sector Hospitals 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012
 
Description REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy 
Organisation Berman Center for Outcomes and Clinical Research
Country United States 
Sector Academic/University 
PI Contribution CTSU co-ordinates the trial.
Collaborator Contribution Local participating centres recruit and follow-up patients.
Impact Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.
Start Year 2012